Shopping Cart
Remove All
Your shopping cart is currently empty
CF-Carvacrol is an orally active lipid-lowering agent synthesized by combining Carvacrol and Clofibric acid. It shows strong affinity for PPAR-α and demonstrates significant hypolipidemic activity. Additionally, CF-Carvacrol exerts antioxidant and anti-inflammatory effects by activating the Nrf2/HO-1 signaling pathway, thereby alleviating liver damage. This compound is applicable in research on liver injury induced by cystic fibrosis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | CF-Carvacrol is an orally active lipid-lowering agent synthesized by combining Carvacrol and Clofibric acid. It shows strong affinity for PPAR-α and demonstrates significant hypolipidemic activity. Additionally, CF-Carvacrol exerts antioxidant and anti-inflammatory effects by activating the Nrf2/HO-1 signaling pathway, thereby alleviating liver damage. This compound is applicable in research on liver injury induced by cystic fibrosis. |
| In vivo | CF-Carvacrol, administered orally at doses of 46.3-185.2 mg/kg (0.1335-0.534 mmol/kg) daily for 7 days, demonstrates a significant dose-dependent lipid-lowering effect in hyperlipidemic Kunming (KM) mice. Furthermore, at a dose of 572.3 g/kg (1.65 mol/kg) given daily for one month, it reduces plasma levels of AST, ALT, and AKP, alleviates oxidative stress and inflammation, and improves liver tissue morphology in KM mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.